natgillin/translations-raw huggingface dataset:
Potentialet for krydsresistens mellem efavirenz og PIer er lille på grund af de forskellige involverede enzymangrebspunkter.
The potential for cross-resistance between efavirenz and PIs is low because of the different enzyme targets involved.
Potentialet for sådanne medikamentelle interaktioner skal overvejes hos patienter ved brug af SIMBRINZA.
The potential for interactions must be considered in patients receiving SIMBRINZA.
Potentialet for, at andre lægemidler påvirker abirateroneksponeringen
Potential for other medicinal products to affect abiraterone exposures
Potentialet for, at eksponeringen for andre lægemidler påvirkes
Potential to affect exposures to other medicinal products
Potentiel forlængelse af QT-intervallet pga. crizotinib er undersøgt hos patienter med enten ALK- positiv eller ROS1-positiv NSCLC behandlet med crizotinib 250 mg 2 gange dagligt.
The QT interval prolongation potential of crizotinib was assessed in patients with either ALK-positive or ROS1-positive NSCLC who received crizotinib 250 mg twice daily.
Potentiel rebound-effekt efter seponering af behandling med AZOPT er ikke studeret; den IOP sænkende effekt forventes at holde 5-7 dage.
Potential rebound effects following cessation of treatment with AZOPT have not been studied; the IOP- lowering effect is expected to last for 5-7 days.
potentiel risiko for
potential risk of cladribine
Potentiel risiko for, at andre lægemidler kan påvirke ulipristalacetat
Potential for other medicinal products to affect ulipristal acetate
Potentiel ↓ i plasmakoncentrationen af ketoconazol forventes.
Potential ↓ in plasma concentrations of ketoconazole are expected.
Potentielle bivirkninger
Potential adverse events
potentielle CYP3A-hæmning (se
potential inhibition of CYP3A by
potentielle fordel anses for at opveje risikoen.
Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.
Potentielle interaktioner med andre lægemidler
Potential for interaction with other medicinal products
Potentielle interaktioner med andre lægemidler
Potential Interactions with other medicinal products
Potentielle interaktioner med antitrombotiske fibrinolytiske midler
Potential Interactions with antithrombotic fibrinolytic agents
Potentielle interaktioner med lægemidler, der hæmmer OCT1, kan ikke udelukkes.
Potential drug interactions with drugs that inhibit OCT1 cannot be excluded.
Potentielle interaktioner med rekombinant t-PA
Potential Interactions with recombinant t-PA
Potentielle interaktioner mellem brivaracetam (50 mg/dag til 200 mg/dag) og andre antiepileptika blev undersøgt i en samlet analyse af lægemiddelkoncentrationer i plasma fra alle fase 2-3 studier i en farmakokinetisk populationsanalyse af placebokontrollerede fase 2-3 studier og i et specifikt lægemiddelinteraktionsstudie (for følgende antiepileptika: carbamazepin, lamotrigin, phenytoin og topiramat).
Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug- drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate).
Potentielle interaktioner mellem brivaracetam (50 mg/dag til 200 mg/dag) og andre antiepileptika blev undersøgt i en samlet analyse af lægemiddelkoncentrationer i plasma fra alle fase 2-3 studier i en farmakokinetisk populationsanalyse af placebokontrollerede fase 2-3 studier og i et specifikt lægemiddelinteraktionsstudie (for følgende antiepileptika: carbamazepin, lamotrigin, phenytoin og topiramat).
Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies, in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug- drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate).
Potentielle interaktioner, der kan påvirke olanzapin
Potential interactions affecting olanzapine
Potentielle komplikationer kan ofte undgås ved at sikre, at patienterne:
Potential complications can often be avoided by ensuring that patients:
Potentielle overfølsomhedsreaktioner eller anafylaktiske reaktioner
Potential for hypersensitivity or anaphylactic reactions
Potentielt alvorlig infektion – tegnene kan være:
Possible serious infection - the signs may include:
Potentielt inficeret biologisk materiale.
Potentially infected biological material.
Potentielt kan blodtryksstigning, bradykardi eller takykardi samt ekstremitets- eller rygsmerter forekomme.
An increase of blood pressure, bradycardia or tachycardia and limb or back pain might be possible.
Potentielt kan høje (op til 700 µM) koncentrationer af eluxadolin i tarmen påvirke farmakokinetikken af samtidigt indgivne CYP3A4-substrater (se pkt.
Potentially high (up to 700 µM) eluxadoline concentrations in gut may affect the pharmacokinetic of concomitantly administered CYP3A4 substrates (see section 4.5).
Potentielt ↓ i plasmakoncentrationen af ketoconazol forventes.
Potencial ↓ in plasma concentrations of ketoconazole are expected.
Potentiering af antikolinerg effekt med anti-parkinson midler og tricykliske antidepressiva kan også forekomme, hvis antimuskarine stoffer bruges samtidig med sådanne lægemidler.
The potentiation of anticholinergic effects with anti- parkinson agents and tricyclic antidepressants may also occur if antimuscarinic agents are used concurrently with such medicinal products.
Potters Bar Hertfordshire EN6 1TL
Potters Bar, EN6 1TL,
Potters Bar Hertfordshire EN6 1TL
Potters Bar, Hertfordshire, EN6 1TL,
Potters Bar Hertfordshire EN6 1TL Storbritannien
Potters Bar Hertfordshire EN6 1TL United Kingdom
Potters Bar, Hertfordshire, EN6 1TL
Potters Bar, Hertfordshire, EN6 1TL,
Potters Bar, Hertfordshire, EN6 1TL, Storbritannien
Generics [UK] Limited
Potters Bar, Hertfordshire, EN6 1TL, Storbritannien
Potters Bar, Hertfordshire, EN6 1TL, UK
Potters Bar, Hertfordshire, EN6 1TL, UK
Generics [UK] Limited
Pottery Road Dun Laoghaire Co Dublin Irland
Dun Laoghaire Co Dublin Ireland
Poulvac E. coli lyofilisat til suspension sprayvaccination til kyllinger og kalkuner eller til brug i drikkevand til kyllinger
Poulvac E. coli lyophilisate for suspension for spray vaccination for chickens and turkeys or for use in drinking water for chickens
Poulvac E. coli virker ligesom andre vacciner ved at "lære" immunsystemet (organismens naturlige forsvar), hvordan det skal forsvare organismen mod en sygdom.
Poulvac E. coli, like all vaccines, works by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease.
Poulvac FluFend H5N3 RG Injektionsvæske, emulsion til kyllinger og ænder
Poulvac FluFend H5N3 RG Emulsion for injection for chickens and ducks
Poulvac FluFend H5N3 RG Vet Injektionsvæske, emulsion til kyllinger og ænder
Poulvac FluFend H5N3 RG emulsion for injection for chickens and ducks
Povidon
Shellac Povidone
Povidon
Tablet core: Povidone
Povidon (E1201) Magnesiumstearat (E470b)
Povidone (E1201) Magnesium stearate (E470b)
Povidon (E1201) Magnesiumstearat.
Lactose monohydrate Povidone (E1201) Magnesium stearate.
Povidon (E1201), mikrokrystallinsk cellulose (E460i), silica, kolloid, vandfri og natriumbenzoat (E211).
Povidone (E1201), Microcrystalline cellulose (E460i), Colloidal anhydrous silica, Sodium benzoate (E211).
Povidon (K 29-32) Magnesiumstearat
Povidone (K 29-32) Magnesium stearate
Povidon (K-25) Kolloid vandfri silika
Silica, colloidal anhydrous
Povidon (K-29/32) Croscarmellosenatrium Natriumstearylfumarat
Povidone (K-29/32) Croscarmellose sodium Sodium stearyl fumarate
Povidon (K30) Benzalkoniumchlorid Dinatriumedetat Vand til injektioner
Povidone (K30) Benzalkonium chloride Disodium edetate Water for injections
Povidon (PVP K-30) Sorbitol (E420) Magnesiumstearat
Povidone (PVP K-30) Sorbitol (E420) Magnesium stearate
Povidon Crospovidon Magnesiumstearat
Povidone Crospovidone Magnesium stearate
Povidon Crospovidon Type A
Povidone Crospovidone Type A
Povidon K 29/32 Croscarmellosenatrium Magnesiumstearat
Povidone K 29/32 Croscarmellose sodium Magnesium stearate
Povidon K25 Glycerol Magnesiumstearat Meglumin Poloxamerer
Povidone K25 Glycerol Magnesium stearate Meglumine Poloxamer
Povidon K25 Prægelatineret stivelse Natriumhydroxid Sorbitol (E420)
Povidone K25 Pregelatinised starch Sodium hydroxide Sorbitol (E420)
Povidon K90 Calciumstearat
Povidone K90 Calcium stearate
Povidon,
Povidone
POWER 1- og POWER 2-studierne.
POWER 1 and POWER 2 trials.
POX-MVA-038: Et observerende, non-interventionsstudie efter markedsføring for den profylaktiske vaccination med IMVANEX til [indsæt beskrivelsen af målpopulationen af vaccinen] markedsføring (PAES)
Non-interventional post-authorisation safety study (PASS) POX-MVA-038: An observational, non-interventional post
PP = pr. protokol-population, ITT = Intent To Treat-population
PP = Per Protocol Population; ITT = Intent To Treat Population
PP- (per protocol) Population
PP (per protocol) Population
PP-population
PP-population
PP-population*
PP-population
PPE (ileitis) & svinedysenteri 4,25 mg/kg legemsvægt
4.25 mg/kg bodyweight
PPE*, alopeci, udslæt
PPE*, alopecia, rash
PPE-populationen bestod af personer, som:
The PPE population consisted of individuals:
Ppramipexoldosis bør reduceres med 0,52 mg base (0,75 mg salt) per dag, indtil den daglige dosis er reduceret til 0,52 mg base (0,75 mg salt).
Pramipexole should be tapered off at a rate of 0.52 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.52 mg of base (0.75 mg of salt).
PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse > 5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size >5 cm
PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size > 5 cm
PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size >5 cm
PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm
PR = progesterone receptor aER/PR-negative or Grade 3 or tumor size >5 cm
PR = progesteronreceptor aER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size >5 cm
PR-interval
PR interval
PR-interval sammenlignet med
in the maximum PR interval
pr. dosering (hver dosering skal gives
administration (each administration to be given morning and evening)
pr. dosis
CCID50 per dose
Pr. dosis (1 ml):
Per dose (1 ml):
Pr. dosis a 2 ml:
Per 2 ml dose:
Pr. dosis af 0,2 ml vaccine:
0.2 ml dose:
Pr. dosis af 1 ml:
Per dose of 1 ml:
Pr. dosis af 1 ml:
≥3550U
Pr. dosis af 2 ml:
Per dose of 2 ml:
Pr. dosis af 2 ml:
Per dose of two ml:
Pr. dosis af to ml:
Per dose of two ml:
Pr. dosis med 2 ml.
Per dose of 2 ml:
Pr. dosis på 2 ml:
Per dose of 2 ml
Pr. dosis à 2 ml.
Per dose of 2 ml:
Pr. dosis:
Per dose:
Pr.-protokol (PP) population (N=39)
Per –Protocol (PP) Population (N=39)
PRAC anbefalede at opdatere produktinformationen for at informere sundhedspersoner og patienter om disse potentielle bivirkninger.
The PRAC recommended updating the product information to inform health professionals and the patients of the potential for these adverse events.
PRAC anbefaler, at hepatitis B- virusstatus fastlægges før påbegyndelse af behandling med thalidomid.
The PRAC recommends that Hepatitis B virus status should be established before initiating treatment with thalidomide.
PRAC anbefaler, at patienter evalueres for tegn og symptomer på underliggende kardiopulmonal sygdom før påbegyndelse af og under behandling med thalidomid.
The PRAC recommends that patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to initiating and during thalidomide therapy.
PRAC anså derfor på baggrund af data fremlagt i den reviderede PSUR ændringerne til produktinformationen for lægemidler indeholdende eribulin som berettigede.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal product containing eribulin were warranted.
PRAC anså tilfældende med seponering og reeksponering for at være vigtige for vurderingen af kausal sammenhæng, da de bidrager til at bekræfte sikkerhedssignalet.
The PRAC considered the cases of dechallenge and rechallenge to be important causal relationship information that contributes to confirm the safety signal.
PRAC bemærkede, at deferasirox ikke kunne udelukkes som potentiel årsag i 3 tilfælde ud af de resterende 38 tilfælde.
Out of the remaining 38 cases, the PRAC observed that deferasirox could not be excluded from potential causality in 3 cases.
PRAC er af den opfattelse, at der er tilstrækkelige beviser, som fører til den konklusion, at alvorlige infektioner under behandling med teriflunomid kan føre til sepsis.
The PRAC is of the opinion that there is enough evidence leading to the conclusion that severe infections during teriflunomide treatment can result to sepsis.
PRAC er blevet opmærksom på at den nuværende advarsel i Erivedge´s produktresumé ikke er tydelig efter nylige henvendelser, som har været modtaget fra farmaceuter og læger, i løbet af sidste måneder, omkring ordinations- og doseringsrestriktioner til fertile kvinder.
Following recent enquiries from pharmacists and prescribers received in the past months regarding prescribing and dispensing restrictions for women of childbearing potential (WCBP), it came to the PRAC’s attention that the current warning in the Erivedge SmPC is not clear.
PRAC finder det uklart hvorvidt dato for graviditetstesten skal tælles som dag 0 eller dag 1.
However, the PRAC considered unclear if the day of negative pregnancy test is counted as day 0 or as day 1.
PRAC har derfor besluttet, at ændringer af produktresuméet er berettiget ud fra de tilgængelige data vedrørende konfusionstilstand.
Therefore, in view of available data regarding confusional state, the PRAC considered that changes to the product information were warranted.
PRAC har derfor på baggrund af de data, der er præsenteret i den gennemgåede PSUR, vurderet, at ændringer til produktinformationen om lægemidler, der indeholder thalidomid, var berettiget.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing thalidomide were warranted.
PRAC har på baggrund af evidens fra rapporter om tilfælde af pulmonal hypertension, nogle dødelige, efter behandling med thalidomid vurderet, at der er et bekræftet kausalt sammenhæng mellem thalidomid og pulmonal hypertension.
The PRAC considered that based on evidence from cases of pulmonary hypertension, some fatal, reported following treatment with thalidomide that there is a confirmed causal association between thalidomide and pulmonary hypertension.
PRAC har på baggrund af evidens fra rapporter om tilfælde af viral reaktivering, nogle alvorlige, efter behandling med thalidomid, især hos patienter tidligere inficeret med herpes zoster- eller hepatitis B-virus (HBV), vurderet, at der er et bekræftet kausalt sammenhæng mellem thalidomid og reaktivering af varizella zoster-virus og hepatitis B-virus (HBV).
The PRAC considered that based on evidence from case reports of viral reactivation, some serious, following treatment with thalidomide, particularly in patients previously infected with the herpes zoster or hepatitis B viruses (HBV), that there is a confirmed causal association between thalidomide and varicella-zoster virus and hepatitis B virus (HBV) reactivation.
PRAC har, i lyset af tilgængeligt data om Fuzeon vurderet, at ændringer i produktinformationen var berettiget.
Therefore, in view of available data regarding Fuzeon, the PRAC considered that changes to the product information were warranted.
PRAC har, i lyset af tilgængeligt data om orlistat vurderet, at ændringer i produktinformationen var berettiget.
Therefore, in view of available data regarding orlistat, the PRAC considered that changes to the product information were warranted.
PRAC konkluderede at risikoen for knoglenekrose (eller knoglevævsdød) i kæben fortsat er meget lav, men har anbefalet en del foranstaltninger til at minimere risikoen.
The PRAC concluded that the risk of osteonecrosis (or death of bone tissue) in the jaw remains very low, but has recommended a number of measures to minimise the risk.
PRAC mener at ændringerne i produktinformationen for lægemidler som indeholder ibandronsyre er påkrævet udfra de informationer som foreligger i PSURen.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the PI of medicinal products containing ibandronic acid were warranted.
PRAC mener derfor at ændringer i produktresuméet og betingelserne for markedsføringstilladelsen er berettiget, baseret på data som er præsenteret i den gennemgåede PSUR,
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information and conditions of the marketing authorisation of medicinal products containing vismodegib were warranted.
PRAC observerede, at teriflunomid ikke kunne udelukkes som en mulig årsag i tilfælde, hvor oplysninger om tid til indtræden, ophør/genoptagelse og seponering af teriflunomid var tilgængelige.
The PRAC observed that teriflunomide could not be excluded from potential causal association in cases where time to onset, de-challenge/rechallenge information and discontinuation were available.
PRAC vurderede derfor på baggrund af foreliggende data om mave-tarm-blødninger ved anvendelsen af apremilast, at ændringer til produktinformationen er berettiget.
Therefore, in view of available data regarding gastrointestinal haemorrhages with the use of apremilast, the PRAC considered that changes to the product information were warranted.
PRAC vurderede, at der, baseret på oplysningerne fra perioden efter markedsføringen, er en bekræftet kausal sammenhæng mellem aflibercept og ovennævnte allergiske reaktioner.
The PRAC considered that based on evidence during post-marketing period that there is a confirmed causal association between aflibercept and the above mentioned hypersensitivity reactions.
PRAC vurderer derfor, i betragtning af de fremlagte oplysninger i den revideret PSUR, at ændringerne skal implementeres i produktinformationen for lægemidler, der indeholder omalizumab.
Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing omalizumab were warranted.
PRAC vurderer, at yderligere risikobegrænsningsforanstaltninger ikke er nødvendige, men af de nye data retfærdiggør en opdatering af advarslen, så den udvides til alle andre karlæsioner i albueregionen, der opstår hos børn, med henblik på bedre at afspejle og karakterisere hudlæsionerne i produktresuméet.
The PRAC considers that no further risk minimization measures are necessary but the new data warrant an update of the warning so that is expanded to any other vascular elbow lesions occurred among children in order to better reflect and characterize skin lesions in the SmPC.
Prac-tic 137,5 mg Pyriprol
Prac-tic 137.5 mg Pyriprole
Prac-tic 137,5 mg spot-on opløsning til små hunde
Prac-tic 137.5 mg spot-on solution for small dogs
Prac-tic 275 mg Pyriprol
Prac-tic 275 mg Pyriprole
Prac-tic 275 mg spot-on opløsning til mellemstore hunde
Prac-tic 275 mg spot-on solution for medium dogs
Prac-tic 56,25 mg Pyriprol
Prac-tic 56.25 mg Pyriprole
Prac-tic 56,25 mg spot-on opløsning til meget små hunde
Prac-tic 56.25 mg spot-on solution for very small dogs
Prac-tic 625 mg Pyriprol
Prac-tic 625 mg Pyriprole
Prac-tic 625 mg spot-on opløsning til store hunde
Prac-tic 625 mg spot-on solution for large dogs
Prac-tic må ikke udledes i vandløb, da det kan være farligt for fisk og andre organismer i vandet.
Prac-tic should not enter water courses as it may be dangerous for fish and other aquatic organisms.
Prac-tic må ikke udledes i vandløb, da dette kan være farligt for fisk og andre vandlevende organismer.
Prac-tic should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Prac-tic spot-on opløsning til hunde
Prac-tic spot-on solution for dogs
Prac-tic spot-on til hunde Pyriprol
Prac-tic spot-on for dogs Pyriprole
Pradaxa 110 mg (kun på karton, ikke på etiket)
Pradaxa 110 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 110 mg er hårde kapsler med en uigennemsigtig, lyseblå hætte og en uigennemsigtig, flødefarvet bund.
Pradaxa 110 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 110 mg hårde kapsler dabigatranetexilat
Pradaxa 110 mg hard capsules Dabigatran etexilate
Pradaxa 110 mg, hårde kapsler
Pradaxa 110 mg hard capsules
Pradaxa 110 mg, hårde kapsler dabigatranetexilat
Pradaxa 110 mg hard capsules dabigatran etexilate
Pradaxa 150 mg (kun på karton, ikke på etiket)
Pradaxa 150 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 150 mg er hårde kapsler med en uigennemsigtig, lyseblå hætte og en uigennemsigtig, flødefarvet bund.
Pradaxa 150 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 150 mg hårde kapsler dabigatranetexilat
Pradaxa 150 mg hard capsules Dabigatran etexilate
Pradaxa 150 mg, hårde kapsler
Pradaxa 150 mg hard capsules
Pradaxa 75 mg (kun på karton, ikke på etiket)
Pradaxa 75 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 75 mg er hårde kapsler med en uigennemsigtig, lyseblå top og en uigennemsigtig, flødefarvet bund.
Pradaxa 75 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 75 mg hårde kapsler dabigatranetexilat
Pradaxa 75 mg hard capsules Dabigatran etexilate
Pradaxa 75 mg, hårde kapsler
Pradaxa 75 mg hard capsules
Pradaxa 75 mg, hårde kapsler dabigatranetexilat
Pradaxa 75 mg hard capsules dabigatran etexilate
Pradaxa anvendes til at behandle blodpropper i vener i ben og lunger og til at forebygge sådanne nye blodpropper.
Pradaxa is a medicine which is used to treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occuring in the vein of your legs and lungs
Pradaxa anvendes til at behandle blodpropper i venerne i ben og lunger, samt forebyggelse af sådanne nye blodpropper.
Pradaxa is a medicine which is used to treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occuring in the vein of your legs and lungs
Pradaxa anvendes til at mindske risikoen for at få en blodprop i hjernen eller andre steder i kroppen hos voksne patienter, der har en unormal hjerterytme (atrieflimren) med andre risikofaktorer.
Pradaxa is a medicine which is used to reduce the risk of brain or body vessel obstruction by blood clot formation in adult patients with an abnormal heart beat (atrial fibrillation) and additional risk factors.
Pradaxa anvendes til:
Pradaxa is used for the following:
Pradaxa blev sammenlignet med warfarin i to hovedundersøgelser af over 5 100 voksne patienter med symptomer på DVT eller lungeemboli, og som i forvejen var blevet behandlet med et injicerbart antikoagulerende middel.
Two main studies in over 5,100 adult patients with symptoms of DVT or PE, and who were initially treated with an injectable anticoagulant, compared Pradaxa with warfarin.
Pradaxa bør ikke anvendes til børn og unge under 18 år.
Pradaxa should not be used in children and adolescents below 18 years old.
Pradaxa dabigatran-etexilat
Pradaxa dabigatran etexilate
Pradaxa er et blodfortyndende lægemiddel, der mindsker risikoen for dannelse af blodpropper.
Pradaxa is a blood thinner medicine that lowers the risk of blood clot formation.
Pradaxa er et lægemiddel, der indeholder det aktive stof dabigatran-etexilat.
Pradaxa is a medicine that contains the active substance dabigatran etexilate.
Pradaxa er kontraindiceret hos patienter med svært nedsat nyrefunktion.
Pradaxa is contraindicated in patients with severe renal impairment